{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:10:58Z","timestamp":1791090658065,"version":"4.1.0"},"reference-count":319,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178121","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:18:02Z","timestamp":1756999082000},"page":"178121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Nanomedicine solutions for inhibiting anastasis and inducing apoptosis to mitigate relapse in treatment-resistant cancers"],"prefix":"10.1016","volume":"1006","author":[{"given":"Seyyed Reza","family":"Hashemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Hosseinpour-Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2311-6554","authenticated-orcid":false,"given":"Amir","family":"Tajbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Nemati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8725-8252","authenticated-orcid":false,"given":"Zahra","family":"Salmasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1700-9426","authenticated-orcid":false,"given":"Amir","family":"Savardashtaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8438-2146","authenticated-orcid":false,"given":"Cambyz","family":"Irajie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178121_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.109922","volume":"104","author":"Abedi","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejphar.2025.178121_bib2","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2147\/IJN.S245135","article-title":"Core\u2013shell imidazoline\u2013functionalized mesoporous silica superparamagnetic hybrid nanoparticles as a potential Theranostic agent for controlled delivery of platinum (II) compound","author":"Abedi","year":"2020","journal-title":"International journal of nanomedicine"},{"key":"10.1016\/j.ejphar.2025.178121_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120685","article-title":"Hierarchical mesoporous zinc-imidazole dicarboxylic acid MOFs: surfactant-directed synthesis, pH-responsive degradation, and drug delivery","volume":"602","author":"Abedi","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib4","series-title":"Two-Dimensional Hybrid Composites: Synthesis, Properties and Applications","first-page":"295","article-title":"Two-dimensional (2D)-Based hybrid composites for cancer diagnosis and therapy","author":"Abedi","year":"2024"},{"key":"10.1016\/j.ejphar.2025.178121_bib5","doi-asserted-by":"crossref","first-page":"16905","DOI":"10.1074\/jbc.M113.536730","article-title":"Delay in apoptosome formation attenuates apoptosis in Mouse Embryonic stem cell differentiation","volume":"289","author":"Akbari-Birgani","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100995","article-title":"Extracellular heat shock proteins and cancer: new perspectives","volume":"14","author":"Albakova","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.104885","article-title":"Regulatory landscape of nanotechnology and nanoplastics from a global perspective","volume":"122","author":"Allan","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178121_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103386","article-title":"Inorganic nanoparticle-based advanced cancer therapies: promising combination strategies","volume":"27","author":"Amaldoss","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2025.178121_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129111","article-title":"Recent advances toward the development of Hsp90 C-terminal inhibitors","volume":"80","author":"Amatya","year":"2023","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2025.178121_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: an update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.ejphar.2025.178121_bib11","series-title":"Advances in Cancer Research","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/bs.acr.2022.11.001","article-title":"Chapter eight - the epigenetic regulation of cancer cell recovery from therapy exposure and its implications as a novel therapeutic strategy for preventing disease recurrence","author":"Appiah","year":"2023"},{"key":"10.1016\/j.ejphar.2025.178121_bib12","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1248\/bpb.b14-00338","article-title":"Construction of an aptamer modified liposomal System targeted to tumor endothelial cells","volume":"37","author":"Ara","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2025.178121_bib13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni.3253","article-title":"Phagocytosis of apoptotic cells in homeostasis","volume":"16","author":"Arandjelovic","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejphar.2025.178121_bib14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ejmech.2014.06.067","article-title":"Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors","volume":"83","author":"Audisio","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.sajb.2022.05.028","article-title":"Natural bioactive products as promising therapeutics: a review of natural product-based drug development","volume":"151","author":"Aware","year":"2022","journal-title":"South Afr. J. Bot."},{"key":"10.1016\/j.ejphar.2025.178121_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrurol.2014.320","article-title":"Targeting heat shock proteins in metastatic castration-resistant prostate cancer","volume":"12","author":"Azad","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2025.178121_bib17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jfda.2018.06.011","article-title":"Prospects of using nanotechnology for food preservation, safety, and security","volume":"26","author":"Bajpai","year":"2018","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.ejphar.2025.178121_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116886","article-title":"Recent advances and molecular mechanisms of TGF-\u03b2 signaling in colorectal cancer, with focus on bioactive compounds targeting","volume":"177","author":"Bakrim","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178121_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107747","article-title":"Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases","volume":"221","author":"Banerjee","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178121_bib20","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s00018-018-2836-6","article-title":"Roles of heat shock factor 1 beyond the heat shock response","volume":"75","author":"Barna","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00204-021-02992-7","article-title":"Nanoparticle-induced inflammation and fibrosis in ex vivo murine precision-cut liver slices and effects of nanoparticle exposure conditions","volume":"95","author":"Bartucci","year":"2021","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178121_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/nano10071403","article-title":"Polymeric nanoparticles for drug delivery: recent developments and future prospects","volume":"10","author":"Begines","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejphar.2025.178121_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107731","article-title":"Failed apoptosis enhances melanoma cancer cell aggressiveness","volume":"31","author":"Berthenet","year":"2020","journal-title":"Cell Rep."},{"issue":"193","key":"10.1016\/j.ejphar.2025.178121_bib24","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.4049\/jimmunol.1401417","article-title":"Functions of heat shock proteins in pathways of the innate and adaptive immune system","author":"Binder","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2025.178121_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/biom12030367","article-title":"The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions","volume":"12","author":"Bouyahya","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2025.178121_bib26","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1242\/jcs.073643","article-title":"Regulation of the Apaf-1-caspase-9 apoptosome","volume":"123","author":"Bratton","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib28","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","article-title":"Updating the definition of cancer","volume":"21","author":"Brown","year":"2023","journal-title":"Mol. Cancer Res. : MCR"},{"key":"10.1016\/j.ejphar.2025.178121_bib29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib30","doi-asserted-by":"crossref","first-page":"9685","DOI":"10.18632\/oncotarget.23859","article-title":"Anticancer activity of biogenerated silver nanoparticles: an integrated proteomic investigation","volume":"9","author":"Buttacavoli","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178121_bib31","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1073\/pnas.0903392106","article-title":"Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models","volume":"106","author":"Caldas-Lopes","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fonc.2012.00026","article-title":"Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer","volume":"2","author":"Cao","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jksus.2016.05.004","article-title":"Silver nanoparticles in polymeric matrices for fresh food packaging","volume":"28","author":"Carbone","year":"2016","journal-title":"J. King Saud Univ. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib34","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood.V112.11.2777.2777","article-title":"The safety, pharmacokinetics and pharmacodynamics of KW-2478, a novel HSP90 antagonist, in patients with B-cell malignancies: a first-in-man, phase I, multicentre, open-label, dose escalation study","volume":"112","author":"Cavenagh","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178121_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2025.178121_bib36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2025.178121_bib37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10555-020-09866-x","article-title":"Integration of EMT and cellular survival instincts in reprogramming of programmed cell death to anastasis","volume":"39","author":"Chakraborty","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejphar.2025.178121_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215925","article-title":"TGF-\u03b2 signaling networks in the tumor microenvironment","volume":"550","author":"Chan","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2025.178121_bib40","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s42247-021-00335-x","article-title":"Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems","volume":"5","author":"Chandrakala","year":"2022","journal-title":"Emergent Mater."},{"key":"10.1016\/j.ejphar.2025.178121_bib41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2010.03.056","article-title":"Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG)","volume":"392","author":"Chandran","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/IGC.0000000000000578","article-title":"Regulatory T cells suppress natural killer cell immunity in patients with human cervical carcinoma","volume":"26","author":"Chang","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ejphar.2025.178121_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091978","article-title":"Targeting heat shock proteins in cancer: a promising therapeutic approach","volume":"18","author":"Chatterjee","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2025.178121_bib45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/anie.201710399","article-title":"Deep-level defect enhanced photothermal performance of bismuth sulfide\u2013gold heterojunction nanorods for photothermal therapy of cancer guided by computed tomography imaging","volume":"57","author":"Cheng","year":"2018","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejphar.2025.178121_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25173982","article-title":"Applications and limitations of dendrimers in biomedicine","volume":"25","author":"Chis","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.178121_bib47","first-page":"219","volume":"vol. 51","author":"Cho","year":"2018"},{"key":"10.1016\/j.ejphar.2025.178121_bib48","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/pharmaceutics17010121","article-title":"Advances in drug targeting, drug delivery, and nanotechnology applications: therapeutic significance in cancer treatment","volume":"17","author":"Ciftci","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178121_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1379\/CSC-99r.1","article-title":"Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications","volume":"10","author":"Ciocca","year":"2005","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.ejphar.2025.178121_bib51","series-title":"To the Edge of Apoptotic Cell Death and Back","author":"Conner","year":"2021"},{"key":"10.1016\/j.ejphar.2025.178121_bib52","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrd2082","article-title":"Drug\u2013target residence time and its implications for lead optimization","volume":"5","author":"Copeland","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.178121_bib53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib54","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1177\/1535370215579167","article-title":"Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy","volume":"240","author":"Dai","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib55","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1007\/s00436-020-06901-2","article-title":"Evaluation of the efficacy of albendazole sulfoxide (ABZ-SO)\u2013loaded chitosan-PLGA nanoparticles in the treatment of cystic echinococcosis in laboratory mice","volume":"119","author":"Darvishi","year":"2020","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3267207","article-title":"Heat shock proteins in cancer immunotherapy","volume":"2019","author":"Das","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2024.213797","article-title":"A versatile theranostic magnetic polydopamine iron oxide NIR laser-responsive nanosystem containing doxorubicin for chemo-photothermal therapy of melanoma","volume":"159","author":"Dehghankhold","year":"2024","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.ejphar.2025.178121_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101119","article-title":"Self-assembled peptide and protein nanostructures for anti-cancer therapy: targeted delivery, stimuli-responsive devices and immunotherapy","volume":"38","author":"Delfi","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.ejphar.2025.178121_bib59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jconrel.2015.02.001","article-title":"Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models","volume":"208","author":"Desale","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.178121_bib60","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10936","article-title":"CasExpress reveals widespread and diverse patterns of cell survival of caspase-3 activation during development in vivo","volume":"5","author":"Ding","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.ejphar.2025.178121_bib61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/15548627.2015.1009776","article-title":"Heat shock response and autophagy--cooperation and control","volume":"11","author":"Dokladny","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.ejphar.2025.178121_bib62","first-page":"2521","article-title":"Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112","volume":"10","author":"Dong","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejphar.2025.178121_bib64","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.2174\/092986708786242895","article-title":"Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket","volume":"15","author":"Donnelly","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib65","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41419-019-1414-7","article-title":"Fhit\u2013Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells","volume":"10","author":"Druck","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.178121_bib66","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/wnan.1390","article-title":"Nanoparticle formulations of cisplatin for cancer therapy","volume":"8","author":"Duan","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.ejphar.2025.178121_bib67","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41388-019-1016-y","article-title":"Heat-shock proteins: chaperoning DNA repair","volume":"39","author":"Dubrez","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2025.178121_bib68","first-page":"723","article-title":"Thymoquinone-loaded mesenchymal stem cell-derived exosome as an efficient nano-system against breast cancer cells","volume":"25","author":"Ebrahimian","year":"2022","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.ejphar.2025.178121_bib69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00280-004-0865-3","article-title":"Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino) ethyl] amino] geldanamycin (17DMAG, NSC 707545) in CB-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts","volume":"55","author":"Eiseman","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178121_bib70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.devcel.2016.06.029","article-title":"The dynamics of apoptotic cell clearance","volume":"38","author":"Elliott","year":"2016","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejphar.2025.178121_bib71","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1039\/c3cs60064e","article-title":"Cytokines as biomarkers of nanoparticle immunotoxicity","volume":"42","author":"Elsabahy","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejphar.2025.178121_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101643","article-title":"Metabolic reprogramming sustains cancer cell survival following extracellular matrix detachment","volume":"36","author":"Endo","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib73","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4049\/jimmunol.177.2.1052","article-title":"CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism","volume":"177","author":"Engelhardt","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2025.178121_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90585-w","article-title":"Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro","volume":"11","author":"Epp-Ducharme","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178121_bib76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2006.07.003","article-title":"Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(\u03b5-caprolactone) micelles","volume":"116","author":"Forrest","year":"2006","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.178121_bib77","first-page":"13791","volume":"100","author":"Fortugno","year":"2003"},{"key":"10.1016\/j.ejphar.2025.178121_bib78","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/cells13110924","article-title":"Apoptosis, a metabolic \u201cHead-to-Head\u201d between tumor and T cells: implications for immunotherapy","volume":"13","author":"Franzese","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178121_bib79","first-page":"4111","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","author":"Fresquet","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.ejphar.2025.178121_bib80","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/ijc.32383","article-title":"HSP70\/HSF1 axis, regulated via a PI3K\/AKT pathway, is a druggable target in chronic lymphocytic leukemia","volume":"145","author":"Frezzato","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178121_bib81","doi-asserted-by":"crossref","first-page":"14739","DOI":"10.1039\/D0NR02291H","article-title":"Functionalized boron nanosheets as an intelligent nanoplatform for synergistic low-temperature photothermal therapy and chemotherapy","volume":"12","author":"Fu","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejphar.2025.178121_bib82","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2025.178121_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/nano9040638","article-title":"Lipid-based nanoparticles: application and recent advances in cancer treatment","volume":"9","author":"Garc\u00eda-Pinel","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejphar.2025.178121_bib84","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4252\/wjsc.v5.i4.188","article-title":"Epithelial-mesenchymal transition-activating transcription factors-multifunctional regulators in cancer","volume":"5","author":"Garg","year":"2013","journal-title":"World J. Stem Cell."},{"key":"10.1016\/j.ejphar.2025.178121_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.02686","article-title":"Hijacking of the AP-1 signaling pathway during development of ATL","volume":"8","author":"Gazon","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejphar.2025.178121_bib86","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2021.02.031","article-title":"Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions","volume":"332","author":"Ghezzi","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.178121_bib87","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819853241","article-title":"Inorganic nanoparticles as drug delivery systems and their potential role in the treatment of chronic myelogenous leukaemia","volume":"18","author":"Ghosn","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178121_bib88","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12943-019-1029-8","article-title":"The role of necroptosis in cancer biology and therapy","volume":"18","author":"Gong","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2025.178121_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1010232","article-title":"Mitochondrial dynamics involves molecular and mechanical events in motility, fusion and fission","volume":"10","author":"Green","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib90","first-page":"1560","volume":"vol. 165","author":"Green","year":"2016"},{"key":"10.1016\/j.ejphar.2025.178121_bib91","article-title":"Advances in peptide-based drug delivery systems","volume":"10","author":"Guo","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2025.178121_bib92","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.2147\/IJN.S168808","article-title":"Main trends of immune effects triggered by nanomedicines in preclinical studies","volume":"13","author":"Halamoda-Kenzaoui","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejphar.2025.178121_bib93","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib94","article-title":"Unravelling the role of solid lipid nanoparticles in drug delivery: Journey from laboratory to clinical trial","volume":"85","author":"Harish","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejphar.2025.178121_bib95","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/1535-7163.MCT-11-0987","article-title":"Antitumor activity of triolimus: a novel multidrug-loaded micelle containing paclitaxel, rapamycin, and 17-AAG","volume":"11","author":"Hasenstein","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2025.178121_bib96","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12247-021-09551-8","article-title":"Mitoxantrone-loaded PLGA nanoparticles for increased sensitivity of glioblastoma cancer cell to TRAIL-induced apoptosis","volume":"17","author":"Hashemi","year":"2021","journal-title":"J. Pharm. Innovat."},{"key":"10.1016\/j.ejphar.2025.178121_bib97","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.aninu.2019.06.005","article-title":"Prospects of HSP70 as a genetic marker for thermo-tolerance and immuno-modulation in animals under climate change scenario","volume":"5","author":"Hassan","year":"2019","journal-title":"Animal Nutrition"},{"key":"10.1016\/j.ejphar.2025.178121_bib98","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1002\/jcp.26585","article-title":"Down\u2010regulation of intracellular anti\u2010apoptotic proteins, particularly c\u2010FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL","volume":"233","author":"Hassanzadeh","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejphar.2025.178121_bib99","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1158\/1078-0432.CCR-08-0221","article-title":"A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer","volume":"14","author":"Heath","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib100","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1158\/0008-5472.CAN-07-3268","article-title":"Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin","volume":"68","author":"Holmes","year":"2008","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178121_bib101","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1039\/D5CB00057B","article-title":"Advances in programmable DNA nanostructures enabling stimuli-responsive drug delivery and multimodal biosensing","volume":"6","author":"Hong","year":"2025","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28167","article-title":"MicroRNAs and proteolytic cleavage of receptors in cancers: a comprehensive review of regulatory interactions and therapeutic implications","volume":"10","author":"Hosseinpour-Soleimani","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2025.178121_bib103","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms19092560","article-title":"The HSP90 family: structure, regulation, function, and implications in health and disease","volume":"19","author":"Hoter","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib104","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178121_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.161","article-title":"Heat shock proteins: biological functions, pathological roles, and therapeutic opportunities","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ejphar.2025.178121_bib106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.freeradbiomed.2020.12.436","article-title":"Small extracellular vesicle-mediated Hsp70 intercellular delivery enhances breast cancer adriamycin resistance","volume":"164","author":"Hu","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib107","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1111\/j.1750-3841.2009.01457.x","article-title":"Bioavailability and delivery of nutraceuticals using nanotechnology","volume":"75","author":"Huang","year":"2010","journal-title":"J. Food Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib108","doi-asserted-by":"crossref","first-page":"14966","DOI":"10.1039\/D5RA01427A","article-title":"Protein-based nanoparticles for antimicrobial and cancer therapy: implications for public health","volume":"15","author":"Ifijen","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejphar.2025.178121_bib109","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/elsc.201800038","article-title":"Silica-based organic-inorganic hybrid nanoparticles and nanoconjugates for improved anticancer drug delivery","volume":"18","author":"Ilhan-Ayisigi","year":"2018","journal-title":"Eng. Life Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib110","article-title":"Nanoparticle technologies in precision oncology and personalized vaccine development: challenges and advances","volume":"10","author":"Imani","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.ejphar.2025.178121_bib111","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s10876-023-02423-w","article-title":"Drug delivery through niosomes: a comprehensive review with therapeutic applications","volume":"34","author":"Izhar","year":"2023","journal-title":"J. Cluster Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib112","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/07357907.2020.1752227","article-title":"HSP90 and co-chaperones: impact on tumor progression and prospects for molecular-targeted cancer therapy","volume":"38","author":"Jafari","year":"2020","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ejphar.2025.178121_bib113","doi-asserted-by":"crossref","DOI":"10.5812\/aapm.103033","article-title":"General anesthetics on immune system cytokines: a narrative review article","volume":"10","author":"Jafarzadeh","year":"2020","journal-title":"Anesthesiol. Pain Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib114","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijpharm.2010.04.027","article-title":"Dendrimer toxicity: let's meet the challenge","volume":"394","author":"Jain","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib115","first-page":"205","volume":"vol. 9","author":"Jan","year":"2019"},{"key":"10.1016\/j.ejphar.2025.178121_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.648463","article-title":"Heat shock proteins and their role in pregnancy: redefining the function of \u201cold rum in a new bottle\u201d","volume":"9","author":"Jee","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib117","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canlet.2010.10.014","article-title":"Targeting heat shock proteins in cancer","volume":"332","author":"Jego","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2025.178121_bib118","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ejmech.2016.10.038","article-title":"Targeting the entry region of Hsp90's ATP binding pocket with a novel 6, 7-dihydrothieno [3, 2-c] pyridin-5 (4H)-yl amide","volume":"124","author":"Jeong","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib119","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/13543784.2014.902442","article-title":"Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions","volume":"23","author":"Jhaveri","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2025.178121_bib120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","article-title":"Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers","volume":"1823","author":"Jhaveri","year":"2012","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib121","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/PO.20.00273","article-title":"Measuring tumor epichaperome expression using [124I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer","volume":"4","author":"Jhaveri","year":"2020","journal-title":"JCO Precision Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib122","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12951-024-02460-1","article-title":"Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer","volume":"22","author":"Jia","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejphar.2025.178121_bib123","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.178121_bib124","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2025.178121_bib125","first-page":"1","article-title":"Chaperones in preventing protein denaturation in living cells and protecting against cellular stress","author":"Kampinga","year":"2006","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178121_bib126","author":"Kandouz"},{"key":"10.1016\/j.ejphar.2025.178121_bib127","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/pharmaceutics15010175","article-title":"Effects of particle geometry for PLGA-based nanoparticles: preparation and in Vitro\/In vivo evaluation","volume":"15","author":"Kaplan","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.178121_bib128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ni0302-221","article-title":"NF-kappaB at the crossroads of life and death","volume":"3","author":"Karin","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejphar.2025.178121_bib129","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/s41386-022-01311-7","article-title":"Nanoparticle delivery systems for substance use disorder","volume":"47","author":"Kasina","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2025.178121_bib130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijpharm.2011.07.033","article-title":"Multi-drug delivery to tumor cells via micellar nanocarriers","volume":"419","author":"Katragadda","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib131","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-immunol-073119-095439","article-title":"Caspases in cell death, inflammation, and pyroptosis","volume":"38","author":"Kesavardhana","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2025.178121_bib132","series-title":"Molecular Pharmaceutics and Nano Drug Delivery","first-page":"237","article-title":"Chapter 10 - dendrimers: promises and challenges in drug delivery","author":"Khatik","year":"2024"},{"key":"10.1016\/j.ejphar.2025.178121_bib133","article-title":"Surface engineered palmitoyl-mesoporous silica nanoparticles with supported lipid bilayer coatings for high-capacity loading and prolonged release of dexamethasone: a factorial design approach","volume":"78","author":"Kheirkhah","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejphar.2025.178121_bib134","article-title":"Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors","volume":"24","author":"Kim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib135","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/ml400082b","article-title":"Effectively delivering a unique hsp90 inhibitor using star polymers","volume":"4","author":"Kim","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2025.178121_bib136","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s12253-019-00643-y","article-title":"Phloretin inhibits the human prostate cancer cells through the generation of reactive oxygen species","volume":"26","author":"Kim","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib137","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-biochem-060208-092442","article-title":"Molecular chaperone functions in protein folding and proteostasis","volume":"82","author":"Kim","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejphar.2025.178121_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/life12111777","article-title":"Heat shock proteins (Hsps) in cellular homeostasis: a promising tool for health management in crustacean aquaculture","volume":"12","author":"Kumar","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.ejphar.2025.178121_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2024.1479993","article-title":"Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials","volume":"6","author":"Kumarasamy","year":"2024","journal-title":"Front. Nanotechnol."},{"key":"10.1016\/j.ejphar.2025.178121_bib140","first-page":"50","volume":"1201","author":"Kushnareva","year":"2010"},{"key":"10.1016\/j.ejphar.2025.178121_bib141","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial\u2013mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.127212","article-title":"Tumor-specific carrier-free nanodrugs with GSH depletion and enhanced ROS generation for endogenous synergistic anti-tumor by a chemotherapy-photodynamic therapy","volume":"407","author":"Lan","year":"2021","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ejphar.2025.178121_bib143","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ygyno.2009.10.078","article-title":"Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy","volume":"117","author":"Landriscina","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib144","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1582-4934.2008.00273.x","article-title":"Heat shock proteins: essential proteins for apoptosis regulation","volume":"12","author":"Lanneau","year":"2008","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib145","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/febs.13970","article-title":"The caspase\u2010activated DN ase: apoptosis and beyond","volume":"284","author":"Larsen","year":"2017","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2025.178121_bib146","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijpharm.2011.08.011","article-title":"Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin","volume":"420","author":"Larson","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib147","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/pharmaceutics12050416","article-title":"Glyceraldehyde-3-phosphate dehydrogenase is a multifaceted therapeutic target","volume":"12","author":"Lazarev","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.178121_bib148","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bbamcr.2011.09.003","article-title":"The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones","volume":"1823","author":"Li","year":"2012","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15092233","article-title":"Recent advances in targeted drug delivery strategy for enhancing oncotherapy","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.178121_bib150","doi-asserted-by":"crossref","first-page":"17064","DOI":"10.1039\/D0NR03907A","article-title":"Rapid synthesis of a Bi@ ZIF-8 composite nanomaterial as a near-infrared-II (NIR-II) photothermal agent for the low-temperature photothermal therapy of hepatocellular carcinoma","volume":"12","author":"Li","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejphar.2025.178121_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","article-title":"Multifunctional nanoparticle-mediated combining therapy for human diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178121_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111847","article-title":"Targeted-delivery of siRNA via a polypeptide-modified liposome for the treatment of gp96 over-expressed breast cancer","volume":"121","author":"Liang","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejphar.2025.178121_bib153","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.7150\/thno.14882","article-title":"HSP90 inhibitor encapsulated photo-theranostic nanoparticles for synergistic combination cancer therapy","volume":"6","author":"Lin","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2025.178121_bib154","article-title":"Editorial: chemo-radiation-resistance in cancer therapy","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178121_bib155","article-title":"Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment","volume":"34","author":"Liu","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejphar.2025.178121_bib156","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.2147\/OTT.S255491","article-title":"Combination of immune checkpoint inhibitors with chemotherapy in lung cancer","volume":"13","author":"Liu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejphar.2025.178121_bib157","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.molcel.2015.03.003","article-title":"Caspase-3 promotes genetic instability and carcinogenesis","volume":"58","author":"Liu","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2025.178121_bib158","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.smim.2017.09.011","article-title":"Effects of engineered nanoparticles on the innate immune system","volume":"34","author":"Liu","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ejphar.2025.178121_bib159","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cbpa.2010.06.176","article-title":"Drug\u2013target residence time: critical information for lead optimization","volume":"14","author":"Lu","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186464","article-title":"Hsp70 and NF-kB mediated control of innate inflammatory responses in a canine macrophage cell line","volume":"21","author":"Lyu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib161","doi-asserted-by":"crossref","unstructured":"Mangla, B., et al., Regulating nanomedicines: challenges, opportunities, and the path forward. Nanomedicine, 1-17.https:\/\/doi.org\/10.1080\/17435889.2025.2533107.","DOI":"10.1080\/17435889.2025.2533107"},{"key":"10.1016\/j.ejphar.2025.178121_bib162","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharmaceut. Bull."},{"key":"10.1016\/j.ejphar.2025.178121_bib163","doi-asserted-by":"crossref","first-page":"37181","DOI":"10.1074\/jbc.M003701200","article-title":"The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone","volume":"275","author":"Marcu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib164","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12929-017-0328-x","article-title":"Evaluation of the use of therapeutic peptides for cancer treatment","volume":"24","author":"Marqus","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejps.2013.04.001","article-title":"Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90","volume":"50","author":"Matokanovic","year":"2013","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib166","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00018-004-4464-6","article-title":"Hsp70 chaperones: cellular functions and molecular mechanism","volume":"62","author":"Mayer","year":"2005","journal-title":"Cell. Mol. Life Sci. : CMLS"},{"key":"10.1016\/j.ejphar.2025.178121_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17218089","article-title":"Impact of gene-environment interactions on cancer development","volume":"17","author":"Mbemi","year":"2020","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.ejphar.2025.178121_bib168","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib169","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-Based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater. Au"},{"key":"10.1016\/j.ejphar.2025.178121_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2022.214482","article-title":"Hybrid nanostructures: versatile systems for biomedical applications","volume":"460","author":"Mehta","year":"2022","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejphar.2025.178121_bib171","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2174\/187152008785914824","article-title":"Recent advances in Hsp90 inhibitors as antitumor agents","volume":"8","author":"Messaoudi","year":"2008","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib172","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib173","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3390\/ijms21041308","article-title":"Intratumor heterogeneity and therapy resistance: contributions of dormancy, apoptosis reversal (anastasis) and cell fusion to disease recurrence","volume":"21","author":"Mirzayans","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.178121_bib176","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-013-2510-5","article-title":"A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer","volume":"139","author":"Modi","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178121_bib177","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12964-022-00880-w","article-title":"Anastasis: cell recovery mechanisms and potential role in cancer","volume":"20","author":"Mohammed","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejphar.2025.178121_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e40072","article-title":"Immobilization of L-Asparaginase on biofunctionalized magnetic graphene oxide nanocomposite: a promising approach for enhanced stability and reusability","volume":"10","author":"Monajati","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2025.178121_bib179","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/ijo.2014.2727","article-title":"Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells","volume":"46","author":"Mori","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib180","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nchembio.670","article-title":"Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90","volume":"7","author":"Moulick","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib181","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3390\/ijms23031685","article-title":"Nanoparticles in clinical translation for cancer therapy","volume":"23","author":"Mundekkad","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib182","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-4939-7477-1_2","article-title":"Role of heat shock factors in stress-induced transcription","volume":"1709","author":"Murshid","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib183","series-title":"Nanostructured Materials for Biomedical Applications","first-page":"339","article-title":"Chapter 11 - protein and peptide nanoparticles for drug delivery applications","author":"Nair","year":"2024"},{"key":"10.1016\/j.ejphar.2025.178121_bib184","first-page":"16","article-title":"Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies","author":"Nair","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.178121_bib185","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/cdd.2017.36","article-title":"Caspase-dependent non-apoptotic processes in development","volume":"24","author":"Nakajima","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2025.178121_bib186","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2216531120","article-title":"Cell survival following direct executioner-caspase activation","volume":"120","author":"Nano","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2025.178121_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1243651","article-title":"Nanoparticles and cytokine response","volume":"11","author":"Nasrullah","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejphar.2025.178121_bib188","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12192-017-0845-2","article-title":"Endogenous epitope tagging of heat shock protein 70 isoform Hsc70 using CRISPR\/Cas9","volume":"23","author":"Nitika","year":"2018","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.ejphar.2025.178121_bib189","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1084\/jem.20040531","article-title":"Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization","volume":"200","author":"Nylandsted","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib190","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/molecules23040907","article-title":"Liposomal drug delivery systems and anticancer drugs","volume":"23","author":"Olusanya","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.178121_bib191","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijpharm.2008.08.024","article-title":"VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer","volume":"365","author":"\u00d6ny\u00fcksel","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib192","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.612354","article-title":"Inhibition of HSP90 as a strategy to radiosensitize glioblastoma: targeting the DNA damage response and beyond","volume":"11","author":"Orth","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib193","first-page":"711","volume":"vol. 26","author":"Osellame","year":"2012"},{"key":"10.1016\/j.ejphar.2025.178121_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124799","article-title":"Effects of nanoparticle size, shape, and zeta potential on drug delivery","volume":"666","author":"\u00d6zt\u00fcrk","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib195","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133210","article-title":"Epigenetic deregulation of apoptosis in cancers","volume":"13","author":"Ozyerli-Goknar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2025.178121_bib196","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2147\/IJN.S275805","article-title":"Hybrid nanoparticles modified by hyaluronic acid loading an HSP90 inhibitor as a novel delivery system for subcutaneous and orthotopic Colon cancer therapy","volume":"16","author":"Pan","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejphar.2025.178121_bib197","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4324-2016150477","article-title":"Liposome and their applications in cancer therapy","volume":"59","author":"Pandey","year":"2016","journal-title":"Braz. Arch. Biol. Technol."},{"key":"10.1016\/j.ejphar.2025.178121_bib198","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2019.05.044","article-title":"The beginning of the end of the nanomedicine hype","volume":"305","author":"Park","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.178121_bib199","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1128\/MCB.22.3.816-834.2002","article-title":"Hsp 27 as a negative regulator of cytochrome C release","volume":"22","author":"Paul","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib200","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15092252","article-title":"A NIR-activated and mild-temperature-sensitive nanoplatform with an HSP90 inhibitor for combinatory chemotherapy and mild photothermal therapy in cancel cells","volume":"15","author":"Peng","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.178121_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2020.105595","article-title":"Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against leishmania infections: preparation, characterization and macrophage uptake","volume":"211","author":"Pires","year":"2020","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejphar.2025.178121_bib202","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/jcb.21707","article-title":"Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities","volume":"104","author":"Plati","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2025.178121_bib203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccr.2005.03.035","article-title":"Rational design of shepherdin, a novel anticancer agent","volume":"7","author":"Plescia","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2025.178121_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152317","article-title":"Nanoparticle-induced immune response: health risk versus treatment opportunity?","volume":"228","author":"Pondman","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.ejphar.2025.178121_bib206","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1016\/j.biomaterials.2013.05.054","article-title":"Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect","volume":"34","author":"Pore","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejphar.2025.178121_bib208","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.carbpol.2015.01.064","article-title":"Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin","volume":"123","author":"Pradhan","year":"2015","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejphar.2025.178121_bib209","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0092-8674(00)80314-1","article-title":"Identification and structural characterization of the ATP\/ADP-binding site in the Hsp90 molecular chaperone","volume":"90","author":"Prodromou","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178121_bib210","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.7150\/thno.106758","article-title":"CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies","volume":"15","author":"Qin","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2025.178121_bib211","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10495-019-01538-8","article-title":"Potential role of anastasis in cancer initiation and progression","volume":"24","author":"Raj","year":"2019","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejphar.2025.178121_bib212","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.18632\/oncotarget.7231","article-title":"Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition","volume":"7","author":"Raja","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178121_bib213","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cstres.2024.05.005","article-title":"An update on the status of HSP90 inhibitors in cancer clinical trials","volume":"29","author":"Rastogi","year":"2024","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.ejphar.2025.178121_bib214","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","article-title":"Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics","volume":"16","author":"Rennick","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejphar.2025.178121_bib215","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ijpharm.2016.07.048","article-title":"Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation","volume":"511","author":"Rochani","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib216","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1544393","article-title":"Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks","volume":"12","author":"Rodr\u00edguez-G\u00f3mez","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib217","doi-asserted-by":"crossref","DOI":"10.1155\/adpp\/1847197","article-title":"The confluence of nanotechnology and heat shock protein 70 in pioneering glioblastoma multiforme therapy: forging pathways towards precision targeting and transformation","author":"Roy","year":"2025","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib218","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jmgm.2016.10.002","article-title":"In silico identification and computational analysis of the nucleotide binding site in the C-terminal domain of Hsp90","volume":"70","author":"Roy","year":"2016","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejphar.2025.178121_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122049","article-title":"Biotin receptor-targeting nanogels loaded with methotrexate for enhanced antitumor efficacy in triple-negative breast cancer in vitro and in vivo models","volume":"624","author":"Sadat Abolmaali","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib221","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.10062","article-title":"Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors","volume":"24","author":"Saif","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib222","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00280-013-2134-9","article-title":"Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors","volume":"71","author":"Saif","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178121_bib223","series-title":"Recent Advances in Nanocarriers for Pancreatic Cancer Therapy","first-page":"15","article-title":"Different combination therapies pertaining to pancreatic cancer","author":"Salmasi","year":"2024"},{"key":"10.1016\/j.ejphar.2025.178121_bib224","article-title":"Dendrimers for drug delivery: an overview of its classes, synthesis, and applications","volume":"98","author":"Sarode","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejphar.2025.178121_bib225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2015.12.053","article-title":"Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells","volume":"499","author":"Sauvage","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib226","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2017.01.013","article-title":"Heat shock proteins and cancer: how can nanomedicine be harnessed?","volume":"248","author":"Sauvage","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.178121_bib227","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.colsurfb.2013.07.031","article-title":"Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme","volume":"112","author":"Saxena","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejphar.2025.178121_bib228","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2012.02.001","article-title":"Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer","volume":"94","author":"Saxena","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejphar.2025.178121_bib229","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejphar.2025.178121_bib230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120724","article-title":"Stromal expression of heat-shock protein 27 is associated with worse clinical outcome in patients with colorectal cancer lung metastases","volume":"10","author":"Schweiger","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178121_bib231","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.587997","article-title":"Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects","volume":"7","author":"Scioli Montoto","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejphar.2025.178121_bib232","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s13402-019-00451-1","article-title":"Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway","volume":"42","author":"Seervi","year":"2019","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib233","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/cpt.1347","article-title":"Efficacy and effectiveness too trials: clinical trial designs to generate evidence on efficacy and on effectiveness in wide practice","volume":"105","author":"Selker","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178121_bib234","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/1573406414666180321151029","article-title":"Towards the in-silico design of new HSP90 inhibitors: molecular docking and 3D-QSAR CoMFA studies of tetrahydropyrido [4, 3-d] pyrimidine derivatives as HSP90 inhibitors","volume":"14","author":"Sepehri","year":"2018","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib235","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1200\/JCO.2010.30.8338","article-title":"Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non\u2013small-cell lung cancer","volume":"28","author":"Sequist","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib236","first-page":"475","article-title":"Synthesis of pore-size-tunable mesoporous silica nanoparticles by simultaneous sol-gel and radical polymerization to enhance silibinin dissolution","volume":"46","author":"Shafiee","year":"2021","journal-title":"Iran. J. Med. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.colcom.2020.100298","article-title":"One-pot synthesis of poly(alkyl methacrylate)-functionalized mesoporous silica hybrid nanocomposites for microencapsulation of poorly soluble phytochemicals","volume":"37","author":"Shafiee","year":"2020","journal-title":"Colloid Interf. Sci.Commun."},{"key":"10.1016\/j.ejphar.2025.178121_bib238","volume":"vol. 5","author":"Shamas-Din","year":"2013"},{"key":"10.1016\/j.ejphar.2025.178121_bib239","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2174\/1389203720666191111113726","article-title":"Physiological functions of heat shock proteins","volume":"21","author":"Shan","year":"2020","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0065-230X(06)95009-X","article-title":"Inhibitors of the HSP90 molecular chaperone: current status","volume":"95","author":"Sharp","year":"2006","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib241","first-page":"2089","article-title":"Inducible HSP70 antagonizes cisplatin-induced cell apoptosis through inhibition of the MAPK signaling pathway in HGC-27 cells","volume":"42","author":"Sheng","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib242","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","article-title":"Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective","volume":"25","author":"Sherafat","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib243","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051263","article-title":"Membrane-associated heat shock proteins in oncology: from basic research to new Theranostic targets","volume":"9","author":"Shevtsov","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178121_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114904","article-title":"Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems","volume":"199","author":"Shi","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2025.178121_bib245","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2025.178121_bib246","doi-asserted-by":"crossref","first-page":"175","DOI":"10.18632\/oncotarget.26544","article-title":"Photo-immune therapy with liposomally formulated phospholipid-conjugated indocyanine green induces specific antitumor responses with heat shock protein-70 expression in a glioblastoma model","volume":"10","author":"Shibata","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.178121_bib247","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1021\/mp2000549","article-title":"A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs","volume":"8","author":"Shin","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib248","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jconrel.2009.04.024","article-title":"Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs","volume":"140","author":"Shin","year":"2009","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.178121_bib249","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2022.103041","article-title":"Indocyanine green conjugated phototheranostic nanoparticle for photodiagnosis and photodynamic therapy","volume":"39","author":"Shinoda","year":"2022","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"10.1016\/j.ejphar.2025.178121_bib250","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2174\/1568026616666160413141911","article-title":"Heat Shock Protein (HSP) drug discovery and development: targeting heat shock proteins in disease","volume":"16","author":"Shrestha","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib251","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drudis.2007.10.007","article-title":"Development and application of Hsp90 inhibitors","volume":"13","author":"Solit","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2025.178121_bib252","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201900250","article-title":"Biomodal tumor\u2010targeted and redox\u2010responsive Bi2Se3 hollow nanocubes for MSOT\/CT imaging guided synergistic low\u2010temperature photothermal radiotherapy","volume":"8","author":"Song","year":"2019","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejphar.2025.178121_bib253","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.socscimed.2015.03.021","article-title":"Patient access to health care and medicines across low-income countries","volume":"133","author":"Srivastava","year":"2015","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib254","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1743-8977-9-20","article-title":"Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity","volume":"9","author":"Stern","year":"2012","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.ejphar.2025.178121_bib255","first-page":"443","volume":"vol. 9","author":"Suhaili","year":"2017"},{"key":"10.1016\/j.ejphar.2025.178121_bib256","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1038\/s41467-020-19068-2","article-title":"Akt1 and dCIZ1 promote cell survival from apoptotic caspase activation during regeneration and oncogenic overgrowth","volume":"11","author":"Sun","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178121_bib257","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1083\/jcb.201706134","article-title":"A molecular signature for anastasis, recovery from the brink of apoptotic cell death","volume":"216","author":"Sun","year":"2017","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib259","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41418-022-01081-1","article-title":"Anastasis confers ovarian cancer cells increased malignancy through elevated p38 MAPK activation","volume":"30","author":"Sun","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2025.178121_bib260","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1039\/D1TB02219A","article-title":"Combined effect of heat shock protein inhibitor geldanamycin and free radicals on photodynamic therapy of prostate cancer","volume":"10","author":"Sun","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejphar.2025.178121_bib261","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1021\/acs.molpharmaceut.4c00188","article-title":"MMP-2 responsive gold nanorods loaded with HSP-70 siRNA for enhanced photothermal tumor therapy","volume":"21","author":"Sun","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib262","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2025.178121_bib263","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Y. Xia Engineered nanoparticles for drug delivery in cancer therapy Angew","volume":"53","author":"Sun","year":"2014","journal-title":"Chem Int Ed"},{"key":"10.1016\/j.ejphar.2025.178121_bib264","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s12274-020-2684-1","article-title":"PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function","volume":"13","author":"Sweeney","year":"2020","journal-title":"Nano Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib265","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrm2952","article-title":"Mitochondria and cell death: outer membrane permeabilization and beyond","volume":"11","author":"Tait","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib266","volume":"vol. 5","author":"Tait","year":"2013"},{"key":"10.1016\/j.ejphar.2025.178121_bib267","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2014.09.001","article-title":"Selective targeting of the stress chaperome as a therapeutic strategy","volume":"35","author":"Taldone","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib268","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jconrel.2020.03.040","article-title":"Nucleic acid-based drug delivery strategies","volume":"323","author":"Tan","year":"2020","journal-title":"J. Contr. Release"},{"issue":"96","key":"10.1016\/j.ejphar.2025.178121_bib270","first-page":"51964","article-title":"Strategies for tracking anastasis, a cell survival phenomenon that reverses apoptosis","volume":"16","author":"Tang","year":"2015","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejphar.2025.178121_bib271","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1091\/mbc.e11-11-0926","article-title":"Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response","volume":"23","author":"Tang","year":"2012","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejphar.2025.178121_bib273","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/sj.bjc.6604802","article-title":"Reversibility of apoptosis in cancer cells","volume":"100","author":"Tang","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.178121_bib274","doi-asserted-by":"crossref","DOI":"10.3791\/54107","article-title":"Detecting anastasis in vivo by caspasetracker biosensor","author":"Tang","year":"2018","journal-title":"JoVE J."},{"key":"10.1016\/j.ejphar.2025.178121_bib276","doi-asserted-by":"crossref","first-page":"43","DOI":"10.12688\/f1000research.10568.1","article-title":"Molecular signature of anastasis for reversal of apoptosis","volume":"6","author":"Tang","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.ejphar.2025.178121_bib277","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41597-022-01470-8","article-title":"Transcriptomic study of anastasis for reversal of ethanol-induced apoptosis in mouse primary liver cells","volume":"9","author":"Tang","year":"2022","journal-title":"Sci. Data"},{"key":"10.1016\/j.ejphar.2025.178121_bib280","article-title":"Anastasis: recovery from the brink of cell death","volume":"5","author":"Tang","year":"2018","journal-title":"R. Soc. Open Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib281","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.240270","article-title":"Unravelling the pathological roles of anastasis in cancer recurrence","volume":"15","author":"Tang","year":"2025","journal-title":"Open Biol"},{"issue":"9_Supplement","key":"10.1016\/j.ejphar.2025.178121_bib283","first-page":"336","article-title":"Preparation of nanoparticle albumin bound 17AAG (nab-17AAG) suitable for intravenous administration","volume":"65","author":"Tao","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib284","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s13205-024-03951-6","article-title":"Heat shock protein paradigms in cancer progression: future therapeutic perspectives","volume":"14","author":"Tausif","year":"2024","journal-title":"3 Biotech"},{"key":"10.1016\/j.ejphar.2025.178121_bib285","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/pharmaceutics17060707","article-title":"Liposomal and lipid-based drug delivery systems: bridging gut microbiota and pediatric disorder treatments","volume":"17","author":"Teleanu","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.178121_bib286","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles\u2500from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejphar.2025.178121_bib287","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13061415","article-title":"Peptide-based nanoparticle for tumor therapy","volume":"13","author":"Thongpon","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178121_bib289","series-title":"PLGA Nanoparticles as Promising Drug Delivery Carrier: the Future of Skin Cancer Treatment","author":"Todaria","year":"2025"},{"key":"10.1016\/j.ejphar.2025.178121_bib290","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.201600194","article-title":"Triolimus: a multi-drug loaded polymeric micelle containing paclitaxel, 17-AAG, and rapamycin as a novel radiosensitizer","volume":"17","author":"Tomoda","year":"2017","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.ejphar.2025.178121_bib291","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3892\/etm.2012.696","article-title":"Involvement of heat shock protein 27 in the susceptibility of KT human breast cancer cells to UVC and interferon lethality","volume":"4","author":"Tong","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejphar.2025.178121_bib292","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/fon.09.30","article-title":"Impact of heat-shock protein 90 on cancer metastasis","volume":"5","author":"Tsutsumi","year":"2009","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejphar.2025.178121_bib293","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.dnarep.2017.06.011","article-title":"Histone ubiquitination in the DNA damage response","volume":"56","author":"Uckelmann","year":"2017","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejphar.2025.178121_bib294","first-page":"2198","article-title":"Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with rous sarcoma virus","volume":"6","author":"Uehara","year":"1986","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib295","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s11671-023-03943-0","article-title":"Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review","volume":"18","author":"Unnikrishnan","year":"2023","journal-title":"Discov Nano"},{"key":"10.1016\/j.ejphar.2025.178121_bib296","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3390\/app15063189","article-title":"Enhancement of EPR effect for passive tumor targeting: current status and future perspectives","volume":"15","author":"Vagena","year":"2025","journal-title":"Appl. Sci."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178121_bib297","article-title":"The role of chromosomal instability in cancer and therapeutic responses","volume":"10","author":"Vargas-Rond\u00f3n","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178121_bib298","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/897348","article-title":"Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids","volume":"2013","author":"Viola","year":"2013","journal-title":"J Drug Deliv"},{"key":"10.1016\/j.ejphar.2025.178121_bib299","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13561-024-00487-6","article-title":"Impact of reimbursement systems on patient care - a systematic review of systematic reviews","volume":"14","author":"Wagenschieber","year":"2024","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.ejphar.2025.178121_bib300","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1158\/1078-0432.CCR-13-0953","article-title":"A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas","volume":"19","author":"Wagner","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib301","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10875-008-9251-y","article-title":"TGF-beta and regulatory T cell in immunity and autoimmunity","volume":"28","author":"Wan","year":"2008","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejphar.2025.178121_bib302","first-page":"95","volume":"vol. 43","author":"Wang","year":"2009"},{"key":"10.1016\/j.ejphar.2025.178121_bib303","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41467-018-02915-8","article-title":"Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178121_bib304","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41578-021-00315-x","article-title":"Multifunctional biomolecule nanostructures for cancer therapy","volume":"6","author":"Wang","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejphar.2025.178121_bib305","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41419-023-05916-8","article-title":"Anastasis enhances metastasis and chemoresistance of colorectal cancer cells through upregulating cIAP2\/NFkappaB signaling","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.178121_bib306","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/med.21637","article-title":"Targeting MDM2 for novel molecular therapy: beyond oncology","volume":"40","author":"Wang","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejphar.2025.178121_bib307","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102651","article-title":"PARP-1 and its associated nucleases in DNA damage response","volume":"81","author":"Wang","year":"2019","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejphar.2025.178121_bib308","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation","volume":"91","author":"Whitesell","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib309","doi-asserted-by":"crossref","first-page":"18297","DOI":"10.1073\/pnas.1421323111","article-title":"HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models","volume":"111","author":"Whitesell","year":"2014","journal-title":"Proc. Nat. Acad. Sci. Uni. Stat. Am."},{"key":"10.1016\/j.ejphar.2025.178121_bib310","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1021\/nn200173u","article-title":"Nano self-assembly of recombinant human gelatin conjugated with \u03b1-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery","volume":"5","author":"Won","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejphar.2025.178121_bib311","doi-asserted-by":"crossref","first-page":"42115","DOI":"10.1021\/acsami.8b16448","article-title":"Chemodrug-gated biodegradable hollow mesoporous organosilica nanotheranostics for multimodal imaging-guided low-temperature photothermal therapy\/chemotherapy of cancer","volume":"10","author":"Wu","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejphar.2025.178121_bib312","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.tips.2016.11.009","article-title":"Heat shock proteins and cancer","volume":"38","author":"Wu","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib313","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178121_bib314","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/jps.21509","article-title":"A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats","volume":"98","author":"Xiong","year":"2009","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejphar.2025.178121_bib316","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jconrel.2008.03.015","article-title":"Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats","volume":"129","author":"Xiong","year":"2008","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.178121_bib317","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202100109","article-title":"Lipid nanoparticles for drug delivery","volume":"2","author":"Xu","year":"2022","journal-title":"Adv. NanoBiomed. Res."},{"key":"10.1016\/j.ejphar.2025.178121_bib319","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.neo.2018.01.005","article-title":"Apoptosis reversal promotes cancer stem cell-like cell formation","volume":"20","author":"Xu","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejphar.2025.178121_bib320","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020248","article-title":"Different targeting ligands-mediated drug delivery systems for tumor therapy","volume":"16","author":"Yan","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.178121_bib321","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178121_bib322","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.2147\/IJN.S93758","article-title":"Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice","volume":"10","author":"Yang","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejphar.2025.178121_bib323","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/molecules25092193","article-title":"Therapeutic nanoparticles and their targeted delivery applications","volume":"25","author":"Yetisgin","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.178121_bib324","first-page":"11","article-title":"Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors","author":"Yin","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejphar.2025.178121_bib325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143266","article-title":"HSP90 inhibitor-loaded hollow mesoporous nanoparticles for enhanced synergistic mild photothermal\/chemotherapy in triple negative breast cancer","volume":"310","author":"Yuan","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178121_bib326","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/cells9010060","article-title":"Heat shock proteins: agents of cancer development and therapeutic targets in anti-cancer therapy","volume":"9","author":"Yun","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178121_bib327","doi-asserted-by":"crossref","DOI":"10.3390\/polym15071596","article-title":"Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems","volume":"15","author":"Yusuf","year":"2023","journal-title":"Polymers"},{"key":"10.1016\/j.ejphar.2025.178121_bib328","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153671","article-title":"Anastasis: return journey from cell death","volume":"13","author":"Zaitceva","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.178121_bib329","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2016.09.043","article-title":"Design, synthesis and pharmacological evaluation of 4, 5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors","volume":"125","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib330","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12951-020-00749-5","article-title":"Synergy of hypoxia relief and heat shock protein inhibition for phototherapy enhancement","volume":"19","author":"Zhang","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejphar.2025.178121_bib331","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121476","article-title":"Preparation of carbon nanotubes and polyhedral oligomeric-reinforced molecularly imprinted polymer composites for drug delivery of gallic acid","volume":"615","author":"Zhang","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib332","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejpb.2015.04.023","article-title":"Phospholipid-stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect","volume":"94","author":"Zhang","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejphar.2025.178121_bib333","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022145","article-title":"TGF-\u03b2 family signaling in the control of cell proliferation and survival","volume":"9","author":"Zhang","year":"2017","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2025.178121_bib334","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejmech.2014.10.034","article-title":"Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors","volume":"89","author":"Zhao","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178121_bib335","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.apsb.2016.07.006","article-title":"Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy","volume":"7","author":"Zhao","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejphar.2025.178121_bib336","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2021.117995","article-title":"Rhenium nanoparticles for the delivery of HSP 90 inhibitors: a new drug delivery platform designed by molecular dynamics simulation","volume":"347","author":"Zhu","year":"2022","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ejphar.2025.178121_bib337","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13050623","article-title":"Nucleoside-lipid-based nanoparticles for phenazine delivery: a new therapeutic strategy to disrupt Hsp27-eIF4E interaction in castration resistant prostate cancer","volume":"13","author":"Ziouziou","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:32:07Z","timestamp":1780201927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":319,"alternative-id":["S0014299925008751"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178121","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanomedicine solutions for inhibiting anastasis and inducing apoptosis to mitigate relapse in treatment-resistant cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178121"}}